Toyama Chemical Licenses Quinolone-type Synthetic Antibacterial Agent, T-3811, to Dong-A Pharmaceutical.Tokyo, Japan, Jan 25, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Toyama Chemical has signed a licensing agreement with Dong-A Pharmaceutical of Korea on T-3811, Toyama Chemical's proprietary quinolone-type synthetic antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this. an·ti·bac·te·ri·al adj. agent. Under the agreement terms, Dong-A will exclusively develop, manufacture and market T-3811 in Korea. Accordingly, Toyama Chemical will receive an upfront payment and royalties from Dong-A. Also, Toyama Chemical will supply the agent and bulk compounds to Dong-A. T-3811, which has a wide antibacterial spectrum, has beneficial effects on gram-positive bacteria including penicillin-resistant pneumococcus pneumococcus Spheroidal bacterium (Streptococcus pneumoniae) that causes human diseases including pneumonia, sinusitis, ear infection, and meningitis. Usually occurring in the upper respiratory tract, this gram-positive (see and methicillin-resistant staphylococcus aureus methicillin-resistant Staphylococcus aureus Methicillin-aminoglycoside resistant Staphylococcus aureus, MRSA An organism with multiple antibiotic resistances–eg, aminoglycosides, chloramphenicol, clindamycin, erythromycin, rifampin, tetracycline, . Toyama Chemical is currently preparing for a new drug application in Japan. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion